R&D | January 21, 2026
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
India in the Changing Landscape of Life-Sciences Research & Development
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
Subscribe To Our Newsletter & Stay Updated
